Psicodélicos no tratamento de transtornos psiquiátricos: Evidências clínicas e desafios éticos
Journal of Medical and Biosciences Research. May 30, 2026 Mickail Ivo Souza, Samuel Cândido Freres, Bruna Aparecida Alves Villafranca et al.
Psychedelics such as psilocybin, MDMA, and ayahuasca show promising results for treatment-resistant depression, anxiety, post-traumatic stress disorder, and substance dependence, especially when combined with supervised psychotherapy. They appear to work through neurobiological mechanisms involving neuroplasticity, brain connectivity, and emotional processing. However, significant challenges remain regarding safety, regulation, patients' psychological vulnerability, and the need for rigorous clinical protocols. The review concludes that psychedelics represent an innovative and potentially transformative perspective in contemporary psychiatry, though more robust studies are needed to consolidate their efficacy, safety, and clinical applicability.